QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=171273F9473C317E58BBE27AC3454FA8;jsessionid=5D1A1E248AE06238DF2E1047151D3590;jsessionid=6FBB62EBC4D065BBC651E2E62D8D8381;jsessionid=00218071F6A4285D9711A9DA21DFCCE7;jsessionid=FC277AAA3502A3CDE1CFCA2902E4FE6B;jsessionid=8C6EA5CEF81179C103EDCE8311EA7C1F (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=171273F9473C317E58BBE27AC3454FA8;jsessionid=5D1A1E248AE06238DF2E1047151D3590;jsessionid=6FBB62EBC4D065BBC651E2E62D8D8381;jsessionid=00218071F6A4285D9711A9DA21DFCCE7;jsessionid=FC277AAA3502A3CDE1CFCA2902E4FE6B;jsessionid=8C6EA5CEF81179C103EDCE8311EA7C1F